艾瑞思姆科技
估值 各估值倍数与自身5年区间的对比
同业对比 Medical Devices
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 艾瑞思姆科技 (IRTC) | 3.58B | -258.71 | 19.26 | 0.00% |
| Abbott Laboratories (ABT) | 181.50B | 33.94 | 3.55 | 2.33% |
| Medtronic (MDT) | 121.20B | 23.34 | 2.41 | 3.01% |
| Stryker Corp (SYK) | 113.02B | 30.53 | 4.71 | 1.18% |
| Boston Scientific (BSX) | 64.33B | 17.97 | 2.58 | 0.00% |
| Edwards Lifesciences (EW) | 49.92B | 50.35 | 4.70 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算2.1%。
合理价值
iRhythm Holdings Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 3% premium over our quantitative fair value estimate of $106.39 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The company's valuation metrics decrease our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. Reflecting the firm's valuation is its enterprise value to EBITDA ratio of 33.7, which falls in the top 20% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be expensive.
The firm's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 0.4%, a core component of profitability, sits in the bottom 30% compared with global peers. The earnings generated by the company relative to its share price is concerning, which further promotes our unfavorable price/fair value ratio.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has been a laggard relative to the broader universe over the past year. While we believe the stock is overvalued, this underperformance had a positive impact on our valuation estimate.
经济护城河
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
艾瑞思姆科技 讨论区 0 条评论